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Toxicity and potential carcinogenicity studies of boric acid were investigated in mice to verify in a second rodent species that this was a noncarcino-
genic chemical. Earlier chronic studies in rats indicated boric acid was not a carcinogen. The chemical is nominated for testing because over 200
tons are produced annually, there are multiple uses for the product, and there is potential for widespread human exposure, both orally and dermally.
Both sexes of B6C3F1 mice were offered diets mixed with boric acid for 14 days, 13 weeks, or 2 years. Dietary doses used in the acute, 14-day
study were 0, 0.62, 1.25, 2.5, 5, and 10%; those in the subchronic, 13-week study were 0, 0.12, 0.25, 0.50, 1, and 2%; and doses in the 2-year,
chronic study were 0, 0.25, and 0.50% in the diet. Mortality, clinical signs of toxicity, estimates of food consumption, body weight gain, and
histopathologic examination of selected tissues constituted the variables measured. In the 14-day study mortality was proportional to dose and time
of exposure in both sexes, occurring in dose groups as low as 2.5% and as early as 7 days of exposure. Body weights were depressed more than
10% below controls in the higher dose groups of both sexes. Mortality in the 13-week study was confined to the two highest dose groups in male
mice and to the 2%-dose group in females. Body weight depression from 8 to 23% below those of controls occurred in the 0.50% and higher dose
groups of both sexes. Minimal to mild extramedullary hematopoiesis in spleens of both sexes was a common occurrence in all dose groups, but the
most severe lesion was testicular degeneration or atrophy of the seminiferous tubules in male mice fed 0.50 to 2.0% boric acid. Dietary doses of
0.25 and 0.50% were selected for both sexes of mice in 2-year studies based on body weights and mortality. Survival of male mice was reduced in
the high-dose group after week 63, and after week 84 in the low-dose group; survival in female mice was not affected at either dose of boric acid.
Reductions in body weight gain occurred in the high-dose group of both sexes. Based on estimates of food consumption, the average amount of
boric acid ingested per mouse per day was calculated to be 400 to 500 mg/kg in the low-dose and 1100 to 1200 mg/kg in the high-dose groups of
both sexes. Again the most prominent lesion was an increased incidence of testicular atrophy (3/49, 6/50, 27/47) and interstitial cell hyperplasia
(0/49, 0/50, 7/47) in high-dose male mice. There was a slight increase in spleen lymphoid depletion in dosed male mice, which was considered
secondary to stress and debilitation. Although there were marginal increases in subcutaneous tissue tumors and hepatic tumors in dosed male
mice, these fell within the historical control range and were not believed to be related to chemical treatment. These particular tumors are highly vari-
able in historical controls, only occurred in the low-dose group, and were not significant by an incidental tumor test, which is appropriate for tumors
that are not a cause of death. There were also no indications that boric acid is genotoxic, since tests with prokaryotic and eukaryotic cells were uni-
formly negative, and there were no effects on sister-chromatid exchanges or chromosomal aberrations in Chinese hamster ovary cells. - Environ
Health Perspect 102(Suppl 7):93-97 (1994)
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Introduction
Boric acid occurs as the natural mineral
sassolite in volcanic waters and hot springs,
and has widespread commercial use in cos-
metics, pharmaceuticals, and industrial
processes (1). The major end uses for boric
acid are in glass manufacturing and as a
fire-retardant in cellulosic insulation (2).
A safe upper limit of 5% boric acid as an
additive to cosmetics was recommended by
the Cosmetic, Toiletry, and Fragrance
Association (CTFA), 1983 (3). The U.S.
Food and Drug Administration (FDA)
ruled that boric acid at <5% was safe but
ineffective as an ocular germicide, safe and
effective as a buffer in ophthalmic prepara-
tions, but unsafe as a skin protectant, oral
antimicrobial, and anorectal antiseptic,
based on the absorption of boric acid by
damaged skin and mucous membranes, its
cumulative toxicity, and its slow elimina-
tion (4). The compound is registered as an
indirect food additive for food packaging,
and tolerances of 8 ppm total boron are
permissible as citrus fruit residues (5).
Boron is mildly irritating to the eyes and
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mucous membranes, with a recommended
threshold limit value (TLV) the same as
that for other nuisance dusts of 10 mg/im3.
Although boric acid is classified as rela-
tively nontoxic, with an acute oral dosage
of LD50>4 g/kg in rats (6), and subcuta-
neous dosage of >1 g/kg in rats (7) and
mice (8), mortality in humans has
occurred after accidental ingestion, or
application to abraded skin (9). These
authors also cited dinical reports ofcentral
nervous system toxicity and toxicity to the
genitourinary tract, liver, and skin in
humans exposed to boric acid at pharmaco-
logic concentrations.
The reproductive toxicity of boric acid
was demonstrable in several rodent studies.
Gavage doses of 1 g/kg per day in albino
rats or dietary doses of 1.0% in Sprague-
Dawley rats caused testicular atrophy after
14 days of gavage (10) or 90 days in the
diet (6), with a no-effect level of about
100 mg/kg per day. Dietary doses of 700
mg/kg for 14 days resulted in mating
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sterility in Sprague-Dawley rats, causing
spermatoxicity in males and decreased
ovulation in females, but lower doses of67
and 200 mg/kg per day did not affect
reproduction through three generations
(6). Ingestion of6 mg/l ofboron equiva-
lents per day for 6 months also caused tes-
ticular atrophy in rats (11).
Ingestion of boric acid resulted in its
accumulation in brain, liver, and fat, and
its excretion into the urine, feces, saliva,
milk, and perspiration (12). Apparently
this compound is poorly absorbed through
intact skin, since there was no chemical
residue in sera of females treated twice
daily for 14 days with vaginal inserts of
600 mg boric acid. However, in infants
with diaper rash or burns (7,13,14) or
adults with burns (15,16) or vaginitis
(17), boric acid absorption occurred
through the compromised dermal layer,
and appeared in the urine.
The Consumer Product Saftey
Commission and the U.S. Enviromental
Protection Agency nominated the chemi-
cal for testing by the National Toxicology
Program (NTP) because over 200 tons are
produced annually (2); there are multiple
uses for the product (3), and there is
potential for widespread human exposure
orally and dermally (1,4,18). Earlier
chronic studies in Sprague-Dawley rats
indicated boric acid is not a carcinogen
(6). Additional prechronic and chronic
studies of boric acid were conducted in
mice to investigate the toxicity of this
widely used product, and to verify in a sec-
ond rodent species that this is a noncar-
cinogenic chemical.
Materials and Methods
Technical-grade boric acid was obtained in
one batch from Thompson Haywood
Chemicals (Kansas City, MO). The sub-
stance was confirmed to be boric acid by
elemental analysis and infrared and ultravi-
olet/visible spectroscopy by Midwest
Reseach Institute (Kansas City, MO).
Cumulative data indicated the boric acid
was approximately 99.7% pure, and was
stable for 2 weeks at 60'C. Periodic char-
acterization ofthe boric acid study materi-
al and a reference standard indicated no
degradation over the course ofthe studies.
Dose mixes were prepared with National
Institute of Health (NIH) 07 rat and
mouse ration, using a Patterson-Kelly V-
blender with intensifier bar, and were
stored at 0° ± 5'C for no longer than 2
weeks. Periodic analyses indicated the dose
mixtures were within 10% of target con-
centrations.
Male and female B6C3F1 mice were
obtained from Charles River Breeding
Laboratories for the 14-day and 13-week
studies, and from Frederick Cancer
Research Center (Frederick, MD) for the
2-year study. Animals were checked for
health status and quarantined for 2 to 3
weeks before studies. They were random-
ized according to body weight, identified,
and placed on studies at 7 to 9 weeks of
age. Animals were maintained five to a
cage in polycarbonate containers with
nonwoven filters on Aspen Bed bedding,
and were given feed ad libitum, and auto-
matic watering. The animal room environ-
ment was maintained at 20.0' to 28.9'C,
11 to 79% humidity, with fluorescent
lighting 12 hr/day, and with 10 to 12
room air changes per hour.
Both sexes ofB6C3F, mice were offered
untreated food or diets mixed with analyti-
cal grade boric acid for 14 days, 13 weeks,
or 2 years. Doses used ranged from 0.62 to
10.0% of the diet in 14-day studies, from
0.12 to 2.0% in 13-week studies; doses
were 0.25 and 0.50% in the 2-year chronic
studies. Mortality, clinical signs oftoxicity,
estimates of food consumption, body
weight gain, selected organ weights, and
histopathologic examination of selected
tissues constituted the variables examined.
Statistical treatment of tumor incidence
data included life table analyses (19,20)
and incidental tumor analyses (21). A
more complete discussion of these meth-
ods can be found in NTP Technical
Report on boric acid (22).
Results
In the 14-day studies 5/5, 3/5, and 1/5
male mice ingesting 10, 5, and 2.5% boric
acid in the diet, respectively, died as early
as day 7 ofexposure; 4/5 female mice died
between days 9 and 11 (Table 1).
Hyperplasia of the forestomach was the
most prominent lesion observed. There
was no apparent effect on food consump-
tion, but body weights were depressed
more than 10% below controls in males
fed 5 or 2.5%, and in females fed 10%
boric acid in the diets.
Mortality in the 13-week studies was
confined to the 1 and 2%-dose groups,
where 8/10 males and 6/10 females fed
2% boric acid died between weeks 1 and
8; one male mouse in the 1%-dose group
died at week 2 of exposure (Table 2).
There was no apparent effect on food con-
sumption, although body weight depres-
sion of 10 to 23% below controls occurred
in males fed 0.50, 1.0, and 2.0% boric
acid, and of8 to 18% in female mice from
the same dose groups. Minimal to mild
extramedullary hematopoiesis in the
spleens ofboth sexes was a common occur-
rence in all dose groups, and hyperkerato-
sis and/or hyperplasia of the forestomach
also occurred in the high-dose group of
both sexes; but the most severe lesion was
testicular degeneration or atrophy of the
seminiferous tubules in male mice fed 0.50
to 2.0% boric acid (Table 3).
Dietary doses of 0.25 and 0.50% were
selected for both sexes of mice in 2-year
studies based on bodyweight depression and
Table 1. Mortality and bodyweights in male and femaleB6CF, mice fed boric acid for 2 weeks.
Mortality Bodyweight, g
Dose % Males Females Males Females
0 0/5 0/5 29.9 ± 0.9 22.3± 0.8
0.62 0/5 0/5 28.4± 1.1 22.0 ±0.9
1.25 0/5 0/5 28.8 ±0.9 21.3 ±0.3
2.5 1/5a 0/5 26.3±1.4 20.7±0.9
5.0 3/5b 0/5 24.6 ±0.2 21.3±0.8
10.0 5/5c 4/5d - 18.4
Day atdeath:a 13; b8, 14, 14; c7, 7, 8, 13, 14; d9, 1111,11.
Table 2. Mortality and bodyweights in male and femaleB6C3F, mice fed boric acid for 13 weeks.
Mortality Bodyweight, g
Dose, % Males Females Males Females
0 0/10 0/10 38.0 29.8
0.12 0/10 0/10 36.8 28.5
0.25 0/10 0/10 37.2 28.5
0.50 0/10 0/10 34.0 27.5
1.0 1/10a 0/10 31.5 26.7
2.0 8/10b 6/10c 29.1 24.3
Week atdeath:a2;b 1, 2, 2, 2, 3, 3, 6, 8;C 1, 2, 3, 3, 5,.6
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Table 3. Incidence of nonneoplasitic lesions in male and female B6C3F1 mice fed boric acid for 13 weeks.
Dose, percent in feed
Site/lesion 0 0.12 0.25 0.50 1.0 2.0
Male
Spleen, extramedullary hematopoiesis 1/10 3/10 5/10 5/10 10/10 1/10
Forestomach, hyperkeratosis and/or hyperplasia 0/10 0/10 0/10 0/10 0/10 8/10
Testis, degeneration/atrophy ofseminiferous tubules 0/10 0/10 0/10 2/10 8/10 8/10
Female
Spleen, extramedullary hematopoiesis 0/10 2/10 4/10 6/10 10/10 2/10
Forestomach, hyperkeratosis and/or hyperplasia 0/10 0/10 0/10 0/10 0/10 3/10
mortality in mice fed 1.0 and 2.0% boric
acid for 13 weeks. Survival rates of male
mice in the 2-year studyfell in the high-dose
group after week 63, and after week 84 in
the low-dose group. Survival in female mice
was not affected at either dose ofboric acid
(Figure 1). There were no apparent effects
on food consumption, but reductions in
body weight gain occurred in the high-dose
group ofboth sexes (Figure 2).
Again the most prominent nonneoplastic
lesion was an increased incidence of testic-
ular atrophy (3/49, 6/50, and 27/47) and
interstitial cell hyperplasia (0/49, 0/50, and
7/47) in control-, low-, and high-dose male
mice (Table 4). The lesion was character-
ized by a variable loss of all stages ofsper-
matocytes, with the seminiferous tubules
containing mainly Sertoli cells, and in
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Figure 1. Kaplan-Meier survival curves for male and
female B6C3F1 mice fed diets containing boric acid for
2 years.
some mice, an increased number of inter-
stitial cells.
There were marginal increases in hepatic
tumors and subcutaneous tissue tumors in
dosed male mice, but these were not
believed to be related to chemical treat-
ment (Table 5). The combined incidence
of hepatocellular adenomas or carcinomas
were 14/50, 19/50, and 15/49 in the
male mice fed 0, 0.25, or 0.50% boric acid,
respectively, for 2 years. The combined
incidences of sarcomas, fibrosarcomas, or
neurofibrosarcomas in the same-dose
groups of male mice were 2/50, 10/50,
and 2/50. None ofthese tumor incidences,
nor any other kinds of tumors, were
increased in female mice.
Mutagenicity assays with Salmonella
typhimurium strains TA98, TA100,
TA1535, and TA1537 were negative in the
presence or absence of S9 fractions pre-
pared from livers ofAroclor 1254-induced
male Sprague-Dawley rats or Syrian ham-
sters. Additional tests in the mouse lym-
phoma L5178Y/TK +/- assay with or
without activation by S9 from Aroclor
1254-induced male F344 rat liverwere also
negative. There were no effects of boric
acid on sister-chromatid exchanges or on
chromosomal aberrations in Chinese ham-
ster ovary cells in the presence or absence
ofS9 fractions from Aroclor 1254-induced
male Sprague-Dawley rat liver (22).
Discussion
The 0.25 and 0.50% doses selected for the
2-year study in mice were good approxima-
tions for a maximum-tolerated dose and
one-half that dose. After about week 30 a
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Figure 2. Growth curves for male and female B6C3F
mice fed diets containing boric acid for 2 years.
dose-related reduction in body weight gain
occurred in both mice sexes. At study ter-
mination average body weights ofsurvivors
were 42.0, 39.1, and 36.5 g in control-,
low-, and high-dose males, and 44.8, 41.8,
and 35.9 g in the same female dose groups.
Unpalatability of the boric acid diets could
account for some of the decrease in body
weight gain, but spillage was also a factor.
Although food consumption appeared to
decrease in chemically treated groups, ina-
nition was probably not a cause of death,
since excess mortality occurred only in
male mice from the high-dose group.
Survival in male mice was reduced after
week 63 in the high-dose, and after week
84 in the low-dose groups, but since five
accidental deaths occurred in male mice
from the high-dose group, these differences
Table 4. Incidence of nonneoplastic lesions in male B6C3F1 mice fed boric acid for 2 years.
Dose, percent in feed
Site/lesion 0 0.25 0.50
Spleen
Lymphoid depletion 5/48 11 /49 25/48
Testis
Degeneration/atrophy of seminiferous tubules 3/49 6/50 27/47
Interstitial cell hyperplasia 0/49 0/50 7/47
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Table 5. Analysis oftumors in maleB6C3F, mice fed boric acid for2 years.
Dose, percent in feed
Site/lesion 0 0.25 0.50
Hepatocellular adenoma orcarcinoma a
Overall rates 14/50 19/50 15/49
Adjusted rates 31.4% 51.4% 50.4%
Terminal rates 11 /41 (21%) 13/30 (43%) 8/22 (36%)
Week offirst observation 92 65 43
Life table tests p= 0.023 p= 0.043 p= 0.038
Incidental tumor tests p=0.183 p= 0.211 p= 0.259
Fibroma, sarcoma, fibrosarcoma, orneurofibrosarcoma b
Overall rates 2/50 10/50 2/50
Adjusted rates 4.9% 26.6% 7.1%
Terminal rates 2/41 (5%) 4/30 (13%) 1/22 (5%)
Week offirst observation 104 82 54
Lifetable tests p=0.239 p= 0.005 p= 0.493
Incidental tumortests p= 0.491 p= 0.026 p= 0.676
a Historical incidence at contract laboratory (mean ± SD): 216/697 (31% ± 9%). Historical incidence in National
Toxicology Program studies: 62/2084 (30% ± 8%). b Historical incidence at contract laboratory (mean ± SD):
39/697 (6% ±4%). Historical incidence in National Toxicology Program studies: 156/2091 (7% ± 8%).
were probably not attributable to chemical
treatment. At study termination there were
41, 30, and 22 male mice; and 33, 33, and
37 female mice in control-, low-, and high-
dose groups available for histologic exami-
nation. The numbers offemales were suffi-
cient to detect the potential toxicologic
effects ofboric acid, but the lower numbers
of males may have reduced the sensitivity
ofthe study.
Just as in the prechronic studies, in the 2-
year study, testicular atrophy and interstitial
cell hyperplasia in male mice were the pre-
dominant lesions related to chemical treat-
ment. Atrophy of the seminiferous tubules
was observed in more than halfofthe male
mice dosed with 0.50% boric acid, but mice
in the 0.25%-dose groups were unaffected.
Similarly, interstitial cell hyperplasia
occurred in 7/47 male mice in the high-dose
group, but not at all in mice from the lower
dose group, indicating a narrow threshold of
male reproductive toxicity for boric acid.
The toxic effects of boric acid on the testis
have been well documented in other rodent
studies (6,10,11). Although testicular toxici-
ty represents the major hazard from this
chemical, these studies used either very high
doses (1000 mg/kg for 14 or 90 days), or
very long durations of exposure (6 mg/1 in
drinking water for 6 months). It is unlikely
that cosmetics that contain 0.10 to 5.0%
boric acid (3), or that nuisance dust levels
from occupational exposure (10 mg/m3 - 1
mg/kg/day in humans) would constitute a
risk ofreproductive toxicity in humans. For
example, since mice normally eat about 4 g
of food per day, best estimates of chemical
consumption for those given 0.25 and
0.50% boric acid for 2 years in the present
study were about 275 and 550 mg/kg/day,
with a no-effect level for testicular toxicity
between these values. Comparable reproduc-
tive toxicity in male rats required about the
same concentrations ofboric acid in the diet,
and a no-effect level of 100 mg/kg/day was
noted (6).
Slight increases in the incidences ofsubcu-
taneous tissue tumors and hepatocellular
tumors occurred in the low-dose group of
male mice, but not in the high-dose group,
nor in either dose group of female mice.
Several factors indicated the occurrence of
these tumors was not related to the adminis-
tration of boric acid. There was a lack of a
relationship between tumor incidence and
dose. The tumors occurred in tissues that
were not target organs, and not in the testes,
the most sensitive site identified for target
organ toxicity, nor in other parts of the
reproductive tracts of either sex. The
increased tumor incidences were significandy
different from concurrent controls only
when calculated by a life table test, which is
inappropriate for tumors that are not a cause
ofdeath. In addition, the incidences ofboth
of these neoplasms are highly variable, and
each fellwithin the range ofreported histori-
cal control values. There were also no indica-
tions that boric acid acted as a genotoxic
agent to induce cancer, since tests with
prokaryotic and eukaryotic cells were uni-
formlynegative, and there were no effects on
sister chromatid exchanges or on chromoso-
mal aberrations in Chinese hamster ovary
cells (22,23).
An earlier 2-year study in Sprague-Dawley
rats showed that boric acid was not carcino-
genic in either sex (6). The present study
confirmed this result in a second species,
showing that boric acid was also not a car-
cinogen in either sexofB6C3Fl mice.
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